v3.23.1
Business acquisition - Narrative (Details)
$ in Thousands
 1 Months Ended 10 Months Ended 12 Months Ended
Dec. 01, 2021
USD ($)
shares
Jun. 14, 2021
USD ($)
shares
Jan. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
shares
Sep. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Business Acquisition [Line Items]                
Income tax benefit           $ 10,411 $ 1,930 $ (382)
Contingent consideration         $ 11,692 11,692 9,856  
Change in fair value of contingent considerations and holdbacks           $ (14,245) (534) $ 0
AbX Biologics, Inc.                
Business Acquisition [Line Items]                
Fair value of consideration transferred $ 102,645              
Cash consideration $ 9,467              
Equity (in shares) | shares 759,601              
Company common stock $ 72,514              
Options consideration 6,400              
Contingent consideration 8,500              
Indemnity holdbacks 12,800              
Net working capital adjustment $ 674              
Contingent consideration, shares issuable up to (in shares) | shares 334,939              
Indemnity holdbacks period 18 months              
Indemnity holdback shares (in shares) | shares 128,351              
Indemnity holdback options (in shares) | shares 15,304              
Holdback before adjustment $ 12,500              
Adjustment holdback shares (in shares) | shares 3,416              
Adjustment holdback options (in shares) | shares 408              
Value of adjustment holdback $ 300              
Post combination compensation expenses includes employee stock awards       $ 41,000        
Vesting period from acquisition date 2 years              
Discount rate         0.096 0.096    
Revenue of acquiree since acquisition date           $ 12,300    
Earnings or loss of acquiree since acquisition date           (6,600)    
Transaction costs           1,500    
Change in fair value during the period         $ 13,471      
Income tax benefit $ 10,500              
Contingent consideration 20,664       $ 7,193 7,193    
Indemnity holdback 12,838              
Fair value of purchase consideration 40,877              
AbX Biologics, Inc. | Awards with vesting requirements                
Business Acquisition [Line Items]                
Post combination compensation expenses includes employee stock awards       $ 17,700        
Vesting period from acquisition date       2 years        
AbX Biologics, Inc. | Awards without vesting requirements                
Business Acquisition [Line Items]                
Post combination compensation expenses includes employee stock awards       $ 3,200        
AbX Biologics, Inc. | Performance Shares                
Business Acquisition [Line Items]                
Post combination compensation expenses includes employee stock awards       $ 20,100   $ 15,400    
iGenomX                
Business Acquisition [Line Items]                
Fair value of consideration transferred   $ 37,653            
Cash consideration   $ 490            
Equity (in shares) | shares   237,409            
Company common stock $ 66,100 $ 26,772 $ 4,600          
Indemnity holdbacks period   18 months            
Discount rate         0.085 0.085    
Transaction costs             800  
Income tax benefit             $ 2,000  
Cash and equity transferred   $ 27,300            
Contingent consideration (in shares) | shares   48,478   59,190        
Contingent consideration   $ 5,500            
Indemnity holdback consideration liability (in shares) | shares   43,662            
Indemnity holdback   $ 4,924            
Fair value of purchase consideration   37,653            
Contingent consideration and indemnity holdback   $ 10,400     $ 4,500 $ 4,500    
Change in fair value of contingent considerations and holdbacks           $ 800